219 related articles for article (PubMed ID: 8055463)
21. Clinical utility of CA 125 in preoperative diagnosis of patients with pelvic masses.
Finkler NJ
Eur J Obstet Gynecol Reprod Biol; 1993 Apr; 49(1-2):105-7. PubMed ID: 8365503
[TBL] [Abstract][Full Text] [Related]
22. [Role of Ca 125 in pelvic masses. Our experience].
Rotondi M; Lauro C; Ammaturo FP; Guerriero V; Rasile M; Panariello S
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):51-4. PubMed ID: 11526720
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
[TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group.
Timmerman D; Van Calster B; Testa AC; Guerriero S; Fischerova D; Lissoni AA; Van Holsbeke C; Fruscio R; Czekierdowski A; Jurkovic D; Savelli L; Vergote I; Bourne T; Van Huffel S; Valentin L
Ultrasound Obstet Gynecol; 2010 Aug; 36(2):226-34. PubMed ID: 20455203
[TBL] [Abstract][Full Text] [Related]
25. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
27. [The estimation of the probability of tumor malignacy on the basis of test combination in the primary diagnosis of adnexal tumors].
Smoleń A; Stachowicz N; Czekierowski A; Kotarski J
Ginekol Pol; 2010 Apr; 81(4):254-61. PubMed ID: 20476596
[TBL] [Abstract][Full Text] [Related]
28. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help.
Valentin L; Ameye L; Savelli L; Fruscio R; Leone FP; Czekierdowski A; Lissoni AA; Fischerova D; Guerriero S; Van Holsbeke C; Van Huffel S; Timmerman D
Ultrasound Obstet Gynecol; 2011 Oct; 38(4):456-65. PubMed ID: 21520475
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography.
Franchi M; Beretta P; Ghezzi F; Zanaboni F; Goddi A; Salvatore S
Acta Obstet Gynecol Scand; 1995 Oct; 74(9):734-9. PubMed ID: 7572110
[TBL] [Abstract][Full Text] [Related]
30. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model.
Timmerman D; Bourne TH; Tailor A; Collins WP; Verrelst H; Vandenberghe K; Vergote I
Am J Obstet Gynecol; 1999 Jul; 181(1):57-65. PubMed ID: 10411796
[TBL] [Abstract][Full Text] [Related]
31. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ultrasound score, CA125, menopausal status, and risk of malignancy index in differentiating between benign and borderline or malignant ovarian tumors.
Leelahakorn S; Tangjitgamol S; Manusirivithaya S; Thongsuksai P; Jaroenchainon P; Jivangkul C
J Med Assoc Thai; 2005 Oct; 88 Suppl 2():S22-30. PubMed ID: 17718292
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
[TBL] [Abstract][Full Text] [Related]
34. Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer.
Torres JC; Derchain SF; Faundes A; Gontijo RC; Martinez EZ; Andrade LA
Sao Paulo Med J; 2002 May; 120(3):72-6. PubMed ID: 12163896
[TBL] [Abstract][Full Text] [Related]
35. Elevation of multiple serum markers in patients with stage I ovarian cancer.
Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
[TBL] [Abstract][Full Text] [Related]
36. Intravenous contrast ultrasound examination using contrast-tuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components.
Testa AC; Timmerman D; Van Belle V; Fruscella E; Van Holsbeke C; Savelli L; Ferrazzi E; Leone FP; Marret H; Tranquart F; Exacoustos C; Nazzaro G; Bokor D; Magri F; Van Huffel S; Ferrandina G; Valentin L
Ultrasound Obstet Gynecol; 2009 Dec; 34(6):699-710. PubMed ID: 19924735
[TBL] [Abstract][Full Text] [Related]
37. Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
Timmerman D; Van Calster B; Jurkovic D; Valentin L; Testa AC; Bernard JP; Van Holsbeke C; Van Huffel S; Vergote I; Bourne T
J Clin Oncol; 2007 Sep; 25(27):4194-200. PubMed ID: 17698805
[TBL] [Abstract][Full Text] [Related]
38. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods.
Meys EMJ; Jeelof LS; Achten NMJ; Slangen BFM; Lambrechts S; Kruitwagen RFPM; Van Gorp T
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):784-792. PubMed ID: 27514486
[TBL] [Abstract][Full Text] [Related]
39. Reliability of IOTA score and ADNEX model in the screening of ovarian malignancy in postmenopausal women.
Nohuz E; De Simone L; Chêne G
J Gynecol Obstet Hum Reprod; 2019 Feb; 48(2):103-107. PubMed ID: 29709594
[TBL] [Abstract][Full Text] [Related]
40. Prospective comparison of ultrasound and computed tomography in the evaluation of gynecologic pelvic masses.
Walsh JW; Rosenfield AT; Jaffe CC; Schwartz PE; Simeone J; Dembner AG; Taylor KJ
AJR Am J Roentgenol; 1978 Dec; 131(6):955-60. PubMed ID: 104597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
